Project A: Hormone Therapy and Risk of Ovarian Cancer. Since 2001, three observational studies have reported a significantly increased risk of invasive epithelial ovarian cancer (IEOC) in association with use of hormone therapy (HT). A 2003 report from the Women's Health Initiative supports this finding. Our combined analysis of 10 observational studies provides strong evidence that risk of IEOC is increased with the use of unopposed estrogen therapy (ET) but the extent of the risk is uncertain. While our analysis also suggests that risk of IEOC may be increased in association with use of estrogen-progestin therapy (EPT), this conclusion is based on fewer data. Additional data are needed to estimate precisely the duration-response relationship for ET and EPT. There is also a need to characterize risk patterns by dose and temporal factors, by other risk factors (e.g., body size), and by histology of IEOC. If HT increases the risk of IEOC, the mechanisms of action are not well-understood. We propose a large population-based case-control study of IEOC in Los Angeles County (LAC) consisting of approximately 952 incident cases and an equal number of control subjects between 45 and 79 years of age. Data from the proposed study will be combined with an additional 986 IEOC and 1,121 controls from three other population-based case-control studies of IEOC we have conducted in LAC during the last decade. In addition to obtaining complete information on HT use, DNA specimens will be obtained from subjects in this proposed study (DNAsamples are already available from 653 cases and 862 controls in our previous studies). The availability of DNA samples on approximately 1,510 IEOC cases and 1,719 control subjects will allow us to conduct a comprehensive investigation of variations in genes, as measured by single nucleotide polymorphisms and haplotypes, involved in HT metabolism, transport or action. We will investigate whether the genetic variants exert independent effects on risk of IEOC and/or modify the HT-IEOC association.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Los Angeles
United States
Zip Code
Praestegaard, Camilla; Jensen, Allan; Jensen, Signe M et al. (2017) Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. Int J Cancer 140:2422-2435
Wang, Sophia S; Luo, Jianning; Cozen, Wendy et al. (2017) Sun sensitivity, indoor tanning and B-cell non-Hodgkin lymphoma risk among Caucasian women in Los Angeles County. Br J Haematol 177:153-156
Kar, Siddhartha P; Adler, Emily; Tyrer, Jonathan et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. Br J Cancer 116:524-535
Rasmussen, Christina B; Kjaer, Susanne K; Albieri, Vanna et al. (2017) Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. Am J Epidemiol 185:8-20
Ma, Huiyan; Ursin, Giske; Xu, Xinxin et al. (2017) Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Res 19:6
Reid, Brett M; Permuth, Jennifer B; Chen, Y Ann et al. (2017) Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 26:116-125
Lawrenson, Kate (see original citation for additional authors) (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675
Winham, Stacey J; Pirie, Ailith; Chen, Yian Ann et al. (2016) Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 25:446-54
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (see original citation for additional authors) (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401
Lee, Alice W; Bomkamp, Ashley; Bandera, Elisa V et al. (2016) A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. Int J Cancer 139:2646-2654

Showing the most recent 10 out of 312 publications